Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023)